Intercept to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 24 2020 - 7:00AM
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical
company focused on the development and commercialization of novel
therapeutics to treat progressive non-viral liver diseases, today
announced that Mark Pruzanski, M.D., President and Chief Executive
Officer, Sandip Kapadia, Chief Financial Officer, and Gail
Cawkwell, M.D., Ph.D., SVP, Medical Affairs, Safety and
Pharmacovigilance of Intercept, will participate in a fireside chat
at the Piper Sandler 32nd Annual Virtual Healthcare Conference on
Tuesday, December 1, 2020 from 3:30 – 3:55 p.m. ET.
A live webcast of the event will be available on the investor
page of Intercept’s website at http://ir.interceptpharma.com. An
audio archive of the webcast will also be available on Intercept’s
website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the
development and commercialization of novel therapeutics to treat
progressive non-viral liver diseases, including primary biliary
cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded
in 2002 in New York, Intercept has operations in the
United States, Europe and Canada. For more
information, please visit www.interceptpharma.com or connect with
the company on Twitter and LinkedIn.
Contact
For more information about Intercept, please contact:
Investor inquiries: investors@interceptpharma.com
Media inquiries: media@interceptpharma.com
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Sep 2023 to Sep 2024